Clinical Trial Update: Brexpiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type [Phase 2, Phase 3]

View source ↗

Summary

This document reports the completion and results posting of a Phase 2/3 clinical trial evaluating brexpiprazole for agitation in Alzheimer's-type dementia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• brexpiprazole (brexpiprazole)

Snippet

Sponsor: Otsuka Pharmaceutical Co., Ltd. | Conditions: Agitation Associated With Dementia of the Alzheimer's Type | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2024-11-14